SoftOx Solutions AS — Regulatory Filings 2021

Oct 19, 2021

FIRST PATIENT ENROLLED IN THE CLINICAL STUDY FOR SOFTOX WOUND TREATMENT AGENT FOR CHRONIC WOUNDS, BIOFILM ERADICATOR (SBE-01 STUDY)

FIRST PATIENT ENROLLED IN THE CLINICAL STUDY FOR SOFTOX WOUND TREATMENT AGENT FOR CHRONIC WOUNDS, BIOFILM ERADICATOR (SBE-01 STUDY)

(SoftOx) We are pleased to announce that the first patient has been recruited to the SBE-01 clinical study. After having experienced unforeseen challenges regarding access to and availability of eligible patients, mainly due to the nationwide nurse strike in Denmark, it is reassuring that the study team has now been able to screen and select several patients for the study, says Glenn Gundersen, Chief Medical Officer in SoftOx Solutions.

SBE-01 (EudraCT no. 2021-000314-42) is the first-in-man (phase I) study with the SoftOx’ lead wound care product, SBE, designed to treat infected chronic wounds. The study will establish a tolerable dose and treatment schedule for SBE to be able to develop it into an effective infection-treatment solution in problematic, non-healing wounds.

For further information, please contact:

CEO Geir Almås of SoftOx Solutions AS, or

CMO, Glenn Gundersen

Mail: ir@soft-ox.com

Mobile: (+47) 948 59 599

About SoftOx Solutions AS

SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian

BioTech company based in Oslo with the aim of helping to combat major threats to

human health, namely the emergence of antimicrobial resistance (AMR), biofilm

infections in chronic wounds and the spread of viruses. For more information on

SoftOx, visit www.soft-ox.com